{"product_id":"1-4-dmaa-hcl-3000-mg-100-mg-ml-30-ml-science-bio-copia","title":"1,4-DMAA HCL · 3000 mg · 100 mg\/mL · 30 mL · Science.bio (stik)","description":"\u003cstyle\u003e\n.accordion .accordion__content,.accordion .accordion__content \u003e *,.product__description,.product__description \u003e *,.product__description .rte,.product__description .rte \u003e *,.rte \u003e .fnx-self,.rte .fnx-self{all:revert;background:transparent!important;color:inherit!important;max-width:none!important;width:100%!important;padding:0!important;margin:0!important;overflow:visible!important;display:block!important}\n.fnx-self{--red:#f87171;--red2:#ef4444;--coral:#fca5a5;--dark:#120604;--dark2:#1e0a08;--copy:#d4b8b5;--line:rgba(248,113,113,.15);all:initial!important;display:block!important;width:100%!important;max-width:none!important;margin:0!important;padding:0!important;color:#fff5f5!important;font-family:Inter,-apple-system,BlinkMacSystemFont,\"Segoe UI\",sans-serif!important;font-size:15px!important;line-height:1.5!important;position:relative!important;box-sizing:border-box!important;overflow:visible!important;background:transparent!important}\n.fnx-self *,.fnx-self *::before,.fnx-self *::after{box-sizing:border-box!important}\n.fnx-self h2,.fnx-self h3{margin-top:0!important}\n.fnx-self p{color:var(--copy)!important;line-height:1.65!important;margin-top:0!important}\n.fnx-self .kicker{display:block!important;margin:0 0 12px!important;color:#f87171!important;font-size:10px!important;font-weight:800!important;letter-spacing:.2em!important;text-transform:uppercase!important}\n.fnx-presentation{position:relative!important;overflow:hidden!important;display:grid!important;grid-template-columns:.85fr 1.15fr!important;gap:clamp(30px,5vw,70px)!important;align-items:end!important;padding:clamp(34px,5vw,62px)!important;margin-bottom:28px!important;border:1px solid rgba(248,113,113,.2)!important;border-radius:28px!important;background:radial-gradient(42rem 27rem at 15% 20%,rgba(239,68,68,.16),transparent 66%),radial-gradient(35rem 25rem at 100% 90%,rgba(220,38,38,.22),transparent 68%),linear-gradient(135deg,rgba(100,20,15,.92),rgba(30,8,6,.97))!important;box-shadow:0 28px 80px rgba(20,4,2,.4),inset 0 1px rgba(255,255,255,.06)!important}\n.fnx-presentation::before{content:\"\";position:absolute;width:55%;height:220%;left:-35%;top:-70%;transform:rotate(17deg);background:linear-gradient(90deg,transparent,rgba(255,255,255,.04),transparent);animation:fnxGlass 9s ease-in-out infinite;pointer-events:none}\n@keyframes fnxGlass{0%,60%{left:-45%;opacity:0}70%{opacity:.7}100%{left:120%;opacity:0}}\n.fnx-presentation-copy{position:relative!important;z-index:2!important;display:block!important}\n.fnx-presentation h2{max-width:11ch!important;margin:0 0 18px!important;color:#fff!important;font-size:clamp(36px,4.5vw,61px)!important;line-height:.98!important;letter-spacing:-.055em!important;font-weight:780!important;display:block!important}\n.fnx-presentation-copy\u003ep:last-child{max-width:39ch!important;margin-bottom:0!important;font-size:15px!important}\n.fnx-facts{display:grid!important;grid-template-columns:repeat(2,minmax(0,1fr))!important;margin:0!important;padding:0!important;list-style:none!important}\n.fnx-fact{display:block!important;min-height:106px!important;padding:20px 22px 20px 0!important;border-top:1px solid rgba(248,113,113,.15)!important;background:transparent!important;margin:0!important}\n.fnx-fact:nth-child(even){padding-left:28px!important;border-left:1px solid rgba(248,113,113,.1)!important}\n.fnx-fact-label{display:block!important;margin:0 0 9px!important;color:#f87171!important;font-size:9px!important;font-weight:800!important;letter-spacing:.16em!important;text-transform:uppercase!important}\n.fnx-fact-value{display:block!important;color:#fff!important;font-size:15px!important;font-weight:700!important;margin:0!important}\n.fnx-stock{display:flex!important;align-items:center!important;gap:9px!important}\n.fnx-stock::before{content:\"\"!important;width:7px!important;height:7px!important;flex:0 0 auto!important;border-radius:50%!important;background:#63ff93!important;box-shadow:0 0 8px #63ff93,0 0 20px rgba(99,255,147,.55)!important}\n.fnx-quick{position:relative!important;overflow:hidden!important;display:block!important;margin:0 0 28px!important;padding:clamp(36px,5vw,58px)!important;border-top:1px solid rgba(248,113,113,.2)!important;border-bottom:1px solid rgba(248,113,113,.14)!important;background:radial-gradient(38rem 22rem at 85% 20%,rgba(239,68,68,.16),transparent 66%),linear-gradient(120deg,rgba(100,20,10,.5),rgba(25,6,4,.75))!important}\n.fnx-quick::after{content:\"\";position:absolute;width:43%;aspect-ratio:1;right:-10%;bottom:-78%;border-radius:50%;background:radial-gradient(circle,rgba(248,113,113,.12),transparent 67%);filter:blur(12px);animation:fnxBreath 7s ease-in-out infinite}\n@keyframes fnxBreath{50%{transform:scale(1.12);opacity:.65}}\n.fnx-quick-head{position:relative!important;z-index:2!important;display:grid!important;grid-template-columns:.95fr .65fr!important;gap:35px!important;align-items:end!important;margin-bottom:30px!important}\n.fnx-quick h2{max-width:12ch!important;margin:0!important;color:#fff!important;font-size:clamp(34px,4vw,52px)!important;line-height:.98!important;letter-spacing:-.05em!important;display:block!important}\n.fnx-quick-head\u003ep{margin-bottom:0!important;max-width:46ch!important;font-size:14px!important}\n.fnx-quick-grid{position:relative!important;z-index:2!important;display:grid!important;grid-template-columns:repeat(4,minmax(0,1fr))!important;border-top:1px solid rgba(248,113,113,.15)!important}\n.fnx-key{position:relative!important;display:block!important;min-height:188px!important;padding:25px 24px 22px 0!important;background:transparent!important;transition:transform .35s ease,background .35s ease}\n.fnx-key+.fnx-key{padding-left:24px!important;border-left:1px solid rgba(248,113,113,.1)!important}\n.fnx-key:hover{transform:translateY(-6px)!important;background:radial-gradient(16rem 10rem at 50% 0,rgba(248,113,113,.08),transparent 70%)!important}\n.fnx-number{display:inline-grid!important;place-items:center!important;width:32px!important;height:32px!important;margin-bottom:23px!important;border:1px solid rgba(248,113,113,.3)!important;border-radius:50%!important;color:#f87171!important;font-size:9px!important;font-weight:800!important;line-height:1!important;padding:0!important;background:transparent!important;vertical-align:top!important;box-shadow:0 0 22px rgba(239,68,68,.1)!important}\n.fnx-key h3{display:block!important;margin:0 0 9px!important;color:#fff!important;font-size:17px!important;font-weight:700!important}\n.fnx-key p{display:block!important;margin:0!important;font-size:13px!important}\n.fnx-deep{position:relative!important;overflow:hidden!important;display:block!important;margin:0!important;border:1px solid rgba(248,113,113,.18)!important;border-radius:27px!important;background:linear-gradient(145deg,rgba(80,15,10,.93),rgba(20,4,2,.98))!important;box-shadow:0 32px 85px rgba(20,4,2,.4),inset 0 1px rgba(255,255,255,.05)!important}\n.fnx-deep\u003esummary{position:relative!important;display:grid!important;grid-template-columns:42px 1fr auto!important;gap:16px!important;align-items:center!important;min-height:96px!important;padding:20px 28px!important;color:#fff!important;cursor:pointer!important;list-style:none!important;background:radial-gradient(34rem 15rem at 10% 0,rgba(248,113,113,.1),transparent 65%)!important}\n.fnx-deep\u003esummary::-webkit-details-marker{display:none!important}\n.fnx-signal{position:relative!important;display:inline-block!important;width:38px!important;height:38px!important;border:1px solid rgba(248,113,113,.4)!important;border-radius:50%!important;background:radial-gradient(circle,#fca5a5 0 2px,transparent 3px)!important;box-shadow:0 0 18px rgba(239,68,68,.14)!important;flex-shrink:0!important}\n.fnx-signal::after{content:\"\";position:absolute;inset:8px;border:1px solid rgba(248,113,113,.16);border-radius:50%;animation:fnxSignal 2.7s ease-in-out infinite}\n@keyframes fnxSignal{50%{transform:scale(1.32);opacity:.2}}\n.fnx-deep-label{display:grid!important;gap:3px!important}\n.fnx-deep-label strong{display:block!important;font-size:18px!important;letter-spacing:.02em!important;color:#fff!important;font-weight:700!important}\n.fnx-deep-label small{display:block!important;color:#c08888!important;font-size:12px!important}\n.fnx-arrow{display:inline-grid!important;place-items:center!important;width:37px!important;height:37px!important;border:1px solid rgba(248,113,113,.28)!important;border-radius:50%!important;color:#f87171!important;background:transparent!important;transition:transform .4s ease;font-size:16px!important}\n.fnx-deep[open] .fnx-arrow{transform:rotate(180deg)!important}\n.fnx-deep-content{display:block!important;animation:fnxOpen .45s ease}\n@keyframes fnxOpen{from{opacity:0;transform:translateY(15px)}}\n.fnx-history{display:grid!important;grid-template-columns:.72fr 1.28fr!important;gap:clamp(38px,6vw,84px)!important;padding:clamp(56px,7vw,92px)!important;border-top:1px solid rgba(248,113,113,.1)!important;background:radial-gradient(40rem 24rem at 15% 25%,rgba(239,68,68,.12),transparent 70%),linear-gradient(145deg,rgba(70,12,8,.98),rgba(50,8,6,.82))!important}\n.fnx-history h2{max-width:8ch!important;margin:0 0 22px!important;color:#fff!important;font-size:clamp(48px,6vw,77px)!important;line-height:.94!important;letter-spacing:-.06em!important;font-weight:780!important;display:block!important}\n.fnx-history-intro\u003ep:last-child{max-width:29ch!important;margin-bottom:0!important}\n.fnx-timeline{position:relative!important;margin:0!important;padding:0 0 0 43px!important;list-style:none!important}\n.fnx-timeline::before{content:\"\";position:absolute;left:8px;top:7px;bottom:8px;width:1px;background:linear-gradient(180deg,#fca5a5,#f87171 30%,#ef4444 72%,transparent);box-shadow:0 0 12px rgba(248,113,113,.6),0 0 28px rgba(239,68,68,.28)}\n.fnx-timeline li{position:relative!important;display:block!important;padding:0 0 43px!important;opacity:.72!important;background:transparent!important;transition:transform .35s ease,opacity .35s ease}\n.fnx-timeline li:last-child{padding-bottom:0!important}\n.fnx-timeline li:hover{opacity:1!important;transform:translateX(6px)!important}\n.fnx-node{position:absolute!important;left:-42px!important;top:4px!important;width:17px!important;height:17px!important;border:1px solid #f87171!important;border-radius:50%!important;background:#3a0a06!important;box-shadow:0 0 0 4px rgba(248,113,113,.05),0 0 12px rgba(248,113,113,.15)!important;transition:background .35s ease,box-shadow .35s ease!important}\n.fnx-timeline li:hover .fnx-node{background:#ffb3a0!important;box-shadow:0 0 0 6px rgba(248,113,113,.08),0 0 18px #f87171,0 0 34px rgba(239,68,68,.5)!important}\n.fnx-date{display:block!important;margin:0 0 7px!important;color:#f87171!important;font-size:9px!important;font-weight:800!important;letter-spacing:.18em!important;text-transform:uppercase!important}\n.fnx-timeline h3{display:block!important;margin:0 0 8px!important;color:#fff!important;font-size:20px!important;font-weight:700!important}\n.fnx-timeline p:last-child{margin-bottom:0!important;font-size:14px!important}\n.fnx-science{display:grid!important;grid-template-columns:1.1fr .9fr!important;gap:clamp(40px,6vw,84px)!important;align-items:center!important;padding:clamp(62px,8vw,106px)!important;border-top:1px solid rgba(248,113,113,.1)!important;background:radial-gradient(48rem 32rem at 22% 50%,rgba(239,68,68,.1),transparent 67%),radial-gradient(48rem 32rem at 90% 15%,rgba(200,30,30,.22),transparent 67%),linear-gradient(130deg,#420a06,#1a0302 72%)!important}\n.fnx-molecule{position:relative!important;min-height:480px!important;display:grid!important;place-items:center!important;perspective:1200px!important}\n.fnx-molecule::before{content:\"\";position:absolute;inset:5%;z-index:0;border-radius:50%;background:radial-gradient(circle,rgba(248,113,113,.32) 0%,rgba(239,68,68,.18) 30%,rgba(200,30,30,.08) 60%,transparent 75%);filter:blur(18px);animation:fnxMolAura 5.5s ease-in-out infinite;pointer-events:none;transition:opacity .5s ease}\n.fnx-molecule:hover::before{opacity:1.8!important;filter:blur(22px)!important}\n@keyframes fnxMolAura{0%,100%{opacity:.55;transform:scale(1)}50%{opacity:1;transform:scale(1.12)}}\n.fnx-molecule-stage{position:relative!important;z-index:2!important;width:100%!important;max-width:560px!important;min-height:390px!important;display:grid!important;place-items:center!important;transform-style:preserve-3d!important;transition:transform .55s cubic-bezier(.16,1,.3,1)!important}\n.fnx-molecule:hover .fnx-molecule-stage{transform:rotateX(-5deg) rotateY(10deg) translateY(-8px) scale(1.04)!important}\n.fnx-molecule-svg{position:relative!important;z-index:3!important;width:108%!important;max-width:580px!important;height:auto!important;display:block!important;filter:drop-shadow(0 0 12px rgba(255,120,100,.85)) drop-shadow(0 0 32px rgba(239,68,68,.55)) drop-shadow(0 0 56px rgba(200,30,30,.3))!important;animation:fnxMolFloat 6.5s ease-in-out infinite!important;transition:filter .55s ease!important}\n.fnx-molecule:hover .fnx-molecule-svg{filter:drop-shadow(0 0 22px rgba(255,100,80,1)) drop-shadow(0 0 55px rgba(239,68,68,.9)) drop-shadow(0 0 90px rgba(220,30,20,.6))!important}\n@keyframes fnxMolFloat{0%,100%{transform:translateY(0) scale(1)}50%{transform:translateY(-10px) scale(1.014)}}\n.fnx-orbit{position:absolute!important;left:50%!important;top:49%!important;width:90%!important;height:42%!important;border:1px solid rgba(248,113,113,.28)!important;border-radius:50%!important;pointer-events:none!important;z-index:1!important}\n.fnx-orbit-a{transform:translate(-50%,-50%) rotate(-10deg)!important;animation:fnxOrbitA 14s linear infinite!important}\n.fnx-orbit-b{width:72%!important;height:58%!important;border-color:rgba(239,68,68,.22)!important;transform:translate(-50%,-50%) rotate(55deg)!important;animation:fnxOrbitB 18s linear infinite!important}\n@keyframes fnxOrbitA{to{transform:translate(-50%,-50%) rotate(350deg)}}\n@keyframes fnxOrbitB{to{transform:translate(-50%,-50%) rotate(415deg)}}\n.fnx-platform{position:absolute!important;left:10%!important;right:10%!important;bottom:4%!important;height:18%!important;z-index:1!important;border-radius:50%!important;background:radial-gradient(ellipse at 50% 40%,rgba(255,160,140,.35),rgba(248,113,113,.22) 18%,rgba(220,38,38,.1) 42%,transparent 70%)!important}\n.fnx-platform::before{content:\"\";position:absolute;inset:28% 8%;border:1px solid rgba(248,113,113,.5);border-radius:50%;box-shadow:0 0 28px rgba(248,113,113,.25),0 0 50px rgba(239,68,68,.12);animation:fnxPlatform 3s ease-in-out infinite}\n@keyframes fnxPlatform{0%,100%{opacity:.7;transform:scale(1)}50%{opacity:1;transform:scale(1.1)}}\n.fnx-molecule-meta{position:absolute!important;left:1%!important;bottom:1%!important;z-index:6!important;padding:12px 15px!important;border-left:2px solid rgba(248,113,113,.5)!important;background:linear-gradient(90deg,rgba(30,4,2,.85),transparent)!important}\n.fnx-molecule-meta strong{display:block!important;color:#ffe8e8!important;font-size:11px!important;letter-spacing:.1em!important}\n.fnx-molecule-meta span{display:block!important;margin-top:5px!important;color:#c08888!important;font-size:9px!important;line-height:1.5!important}\n.fnx-science-copy h2{max-width:11ch!important;margin:0 0 20px!important;color:#fff!important;font-size:clamp(42px,5vw,67px)!important;line-height:.96!important;letter-spacing:-.055em!important;display:block!important}\n.fnx-science-lead{margin-bottom:32px!important;font-size:15px!important}\n.fnx-topics{display:grid!important}\n.fnx-topic{display:grid!important;grid-template-columns:38px 1fr!important;gap:14px!important;padding:18px 0!important;border-top:1px solid rgba(248,113,113,.15)!important;transition:transform .3s ease!important}\n.fnx-topic:hover{transform:translateX(7px)!important}\n.fnx-topic\u003espan{display:block!important;color:#f87171!important;font-size:10px!important;font-weight:800!important}\n.fnx-topic h3{display:block!important;margin:0 0 5px!important;color:#fff!important;font-size:16px!important;font-weight:700!important}\n.fnx-topic p{display:block!important;margin:0!important;font-size:13px!important}\n.fnx-benefits{display:grid!important;grid-template-columns:1fr 1fr!important;gap:clamp(30px,5vw,60px)!important;padding:clamp(58px,7vw,92px)!important;border-top:1px solid rgba(248,113,113,.1)!important;background:radial-gradient(40rem 24rem at 90% 20%,rgba(239,68,68,.12),transparent 70%),linear-gradient(145deg,rgba(50,10,6,.98),rgba(35,6,4,.82))!important}\n.fnx-benefits-intro h2{max-width:10ch!important;margin:0 0 18px!important;color:#fff!important;font-size:clamp(38px,4.5vw,58px)!important;line-height:.98!important;letter-spacing:-.05em!important;display:block!important}\n.fnx-benefits-intro p{font-size:14px!important;margin-bottom:0!important}\n.fnx-benefits-grid{display:grid!important;gap:0!important}\n.fnx-benefit{display:grid!important;grid-template-columns:38px 1fr!important;gap:14px!important;padding:18px 0!important;border-top:1px solid rgba(248,113,113,.15)!important;background:transparent!important;transition:transform .3s ease}\n.fnx-benefit:hover{transform:translateX(7px)!important}\n.fnx-benefit-num{display:block!important;color:#f87171!important;font-size:10px!important;font-weight:800!important;padding-top:2px!important;line-height:1.4!important}\n.fnx-benefit h3{display:block!important;margin:0 0 5px!important;color:#fff!important;font-size:16px!important;font-weight:700!important}\n.fnx-benefit p{display:block!important;margin:0!important;font-size:13px!important}\n.fnx-audience{display:grid!important;grid-template-columns:.62fr 1.38fr!important;gap:clamp(38px,6vw,84px)!important;padding:clamp(58px,7vw,92px)!important;border-top:1px solid rgba(248,113,113,.1)!important;background:radial-gradient(40rem 24rem at 100% 10%,rgba(239,68,68,.14),transparent 70%),linear-gradient(150deg,rgba(60,12,8,.92),rgba(18,4,2,.98))!important}\n.fnx-audience h2{max-width:9ch!important;margin:0!important;color:#fff!important;font-size:clamp(42px,5vw,64px)!important;line-height:.96!important;letter-spacing:-.055em!important;display:block!important}\n.fnx-audience-grid{display:grid!important;gap:0!important}\n.fnx-audience-item{display:block!important;padding:20px 0!important;border-top:1px solid rgba(248,113,113,.15)!important;background:transparent!important}\n.fnx-audience-item h3{display:block!important;margin:0 0 7px!important;color:#fff!important;font-size:17px!important;font-weight:700!important}\n.fnx-audience-item p{display:block!important;margin:0!important;font-size:13.5px!important}\n.fnx-questions{display:grid!important;grid-template-columns:.62fr 1.38fr!important;gap:clamp(38px,6vw,84px)!important;padding:clamp(58px,7vw,92px)!important;border-top:1px solid rgba(248,113,113,.1)!important;background:radial-gradient(40rem 24rem at 0% 50%,rgba(239,68,68,.1),transparent 70%),linear-gradient(150deg,rgba(40,8,5,.92),rgba(14,3,2,.98))!important}\n.fnx-questions h2{max-width:9ch!important;margin:0!important;color:#fff!important;font-size:clamp(42px,5vw,64px)!important;line-height:.96!important;letter-spacing:-.055em!important;display:block!important}\n.fnx-question{display:block!important;padding:20px 0!important;border-top:1px solid rgba(248,113,113,.15)!important;background:transparent!important}\n.fnx-question h3{display:block!important;margin:0 0 7px!important;color:#fff!important;font-size:17px!important;font-weight:700!important}\n.fnx-question p{display:block!important;margin:0!important;font-size:13.5px!important}\n.fnx-close{position:relative!important;overflow:hidden!important;display:grid!important;grid-template-columns:1.25fr .75fr!important;gap:clamp(30px,5vw,65px)!important;align-items:center!important;margin:0!important;padding:clamp(38px,5vw,62px)!important;border-top:1px solid rgba(248,113,113,.22)!important;background:radial-gradient(34rem 22rem at 5% 0,rgba(239,68,68,.14),transparent 68%),radial-gradient(30rem 24rem at 105% 50%,rgba(220,38,38,.22),transparent 67%),linear-gradient(145deg,#3c0c08,#0c0302)!important}\n.fnx-close::after{content:\"\";position:absolute;right:-12%;top:-75%;width:55%;aspect-ratio:1;border:1px solid rgba(248,113,113,.16);border-radius:50%;box-shadow:0 0 35px rgba(248,113,113,.07)}\n.fnx-close-copy,.fnx-actions{position:relative!important;z-index:2!important;display:block!important}\n.fnx-close h2{max-width:17ch!important;margin:8px 0 15px!important;color:#fff!important;font-size:clamp(31px,4vw,52px)!important;line-height:1.02!important;letter-spacing:-.045em!important;font-weight:780!important;display:block!important}\n.fnx-close-copy\u003ep:last-child{max-width:62ch!important;margin-bottom:0!important;font-size:14px!important}\n.fnx-actions{display:grid!important;gap:14px!important}\n.fnx-self a.fnx-btn{display:block!important;width:100%!important;padding:18px 28px!important;border-radius:10px!important;font-family:inherit!important;font-size:13px!important;font-weight:700!important;letter-spacing:.08em!important;line-height:1.2!important;text-align:center!important;text-decoration:none!important;text-transform:uppercase!important;cursor:pointer!important;transition:transform .28s ease,box-shadow .28s ease,background .28s ease!important}\n.fnx-self a.fnx-btn-primary{color:#fff5f5!important;background:rgba(140,20,12,.8)!important;border:1px solid rgba(248,113,113,.62)!important;box-shadow:0 0 20px rgba(239,68,68,.24)!important}\n.fnx-self a.fnx-btn-primary:hover{background:rgba(190,30,18,.9)!important;transform:translateY(-3px)!important}\n.fnx-self a.fnx-btn-secondary{color:rgba(255,185,180,.75)!important;background:transparent!important;border:1px solid rgba(248,113,113,.28)!important}\n.fnx-self a.fnx-btn-secondary:hover{color:#fca5a5!important;border-color:rgba(248,113,113,.44)!important;background:rgba(239,68,68,.07)!important;transform:translateY(-3px)!important}\n@media(max-width:900px){.fnx-presentation,.fnx-quick-head,.fnx-history,.fnx-science,.fnx-benefits,.fnx-audience,.fnx-questions,.fnx-close{grid-template-columns:1fr!important}.fnx-quick-grid{grid-template-columns:repeat(2,minmax(0,1fr))!important}.fnx-molecule{min-height:380px!important}}\n@media(max-width:620px){.fnx-presentation{padding:34px 21px!important;border-radius:22px!important}.fnx-facts{grid-template-columns:1fr!important}.fnx-fact,.fnx-fact:nth-child(even){min-height:0!important;padding:16px 0!important;border-left:0!important}.fnx-quick{padding:38px 20px!important}.fnx-quick-grid{grid-template-columns:1fr!important}.fnx-key,.fnx-key+.fnx-key{min-height:0!important;padding:21px 0!important;border-left:0!important;border-top:1px solid rgba(248,113,113,.15)!important}.fnx-deep{border-radius:22px!important}.fnx-deep\u003esummary{grid-template-columns:35px 1fr auto!important;gap:11px!important;padding:18px 15px!important}.fnx-history,.fnx-science,.fnx-benefits,.fnx-audience,.fnx-questions,.fnx-close{padding:47px 20px!important}.fnx-molecule{min-height:300px!important}.fnx-molecule-svg{width:115%!important}.fnx-close{grid-template-columns:1fr!important}}\n@media(prefers-reduced-motion:reduce){.fnx-self *,.fnx-self *::before,.fnx-self *::after{animation:none!important;transition:none!important}}\n\u003c\/style\u003e\n\u003cdiv class=\"fnx-self\"\u003e\n\u003csection class=\"fnx-presentation\"\u003e\n\u003cdiv class=\"fnx-presentation-copy\"\u003e\n\u003cp class=\"kicker\"\u003eESTA PRESENTACIÓN · RESEARCH USE ONLY\u003c\/p\u003e\n\u003ch2\u003eAmina simpaticomética de alta pureza.\u003c\/h2\u003e\n\u003cp\u003e1,4-DMAA HCl · 100 mg\/mL · 30 mL · Science.bio. Solución líquida para investigación adrenérgica comparativa de isómeros.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-facts\"\u003e\n\u003cdiv class=\"fnx-fact\"\u003e\n\u003cp class=\"fnx-fact-label\"\u003eMarca\u003c\/p\u003e\n\u003cp class=\"fnx-fact-value\"\u003eScience.bio\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-fact\"\u003e\n\u003cp class=\"fnx-fact-label\"\u003ePresentación\u003c\/p\u003e\n\u003cp class=\"fnx-fact-value\"\u003e30 mL · 100 mg\/mL · Gotero\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-fact\"\u003e\n\u003cp class=\"fnx-fact-label\"\u003eContenido declarado\u003c\/p\u003e\n\u003cp class=\"fnx-fact-value\"\u003e3,000 mg totales · CAS 105-41-9\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-fact\"\u003e\n\u003cp class=\"fnx-fact-label\"\u003eDisponibilidad\u003c\/p\u003e\n\u003cp class=\"fnx-fact-value fnx-stock\"\u003eEn existencia · RUO\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"fnx-quick\"\u003e\n\u003cdiv class=\"fnx-quick-head\"\u003e\n\u003cdiv\u003e\n\u003cp class=\"kicker\"\u003eLO ESENCIAL EN SEGUNDOS\u003c\/p\u003e\n\u003ch2\u003e1,4-DMAA HCl, en cuatro claves.\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cp\u003eLo que necesitas saber antes de decidir: estructura, mecanismo, presentación y diferencial del isómero 1,4 respecto al 1,3-DMAA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-quick-grid\"\u003e\n\u003carticle class=\"fnx-key\"\u003e\u003cspan class=\"fnx-number\"\u003e01\u003c\/span\u003e\n\u003ch3\u003eAmina simpaticomética\u003c\/h3\u003e\n\u003cp\u003eEstructura alifática ramificada relacionada con la efedrina. Libera norepinefrina y dopamina con inicio de acción rápido y marcada actividad adrenérgica central.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-key\"\u003e\u003cspan class=\"fnx-number\"\u003e02\u003c\/span\u003e\n\u003ch3\u003eAgonismo α\/β-Adrenérgico\u003c\/h3\u003e\n\u003cp\u003eActiva receptores adrenérgicos centrales y periféricos: incrementa alerta, energía, frecuencia cardíaca y termogénesis de forma dosis-dependiente.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-key\"\u003e\u003cspan class=\"fnx-number\"\u003e03\u003c\/span\u003e\n\u003ch3\u003e100 mg\/mL · Gotero\u003c\/h3\u003e\n\u003cp\u003e3,000 mg en 30 mL. Dosificación precisa de 10–25 mg (0.1–0.25 mL). Formulación líquida para administración exacta en protocolos de investigación.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-key\"\u003e\u003cspan class=\"fnx-number\"\u003e04\u003c\/span\u003e\n\u003ch3\u003eIsómero 1,4 — Perfil diferenciado\u003c\/h3\u003e\n\u003cp\u003eSelectividad adrenérgica distinta al 1,3-DMAA. Material de referencia para investigación comparativa de isómeros, farmacología y metabolismo energético.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdetails class=\"fnx-deep\" open=\"\"\u003e\n\u003csummary\u003e\u003cspan class=\"fnx-signal\"\u003e\u003c\/span\u003e\u003cspan class=\"fnx-deep-label\"\u003e\u003cstrong\u003ePROFUNDIZA\u003c\/strong\u003e\u003csmall\u003eHistoria · molécula · mecanismo · identidad química · preguntas clave\u003c\/small\u003e\u003c\/span\u003e\u003cspan class=\"fnx-arrow\"\u003e↓\u003c\/span\u003e\u003c\/summary\u003e\n\u003cdiv class=\"fnx-deep-content\"\u003e\n\u003csection class=\"fnx-history\"\u003e\u003cheader class=\"fnx-history-intro\"\u003e\n\u003cp class=\"kicker\"\u003eHISTORIA Y CONTEXTO\u003c\/p\u003e\n\u003ch2\u003eDel descongestionante al RUO.\u003c\/h2\u003e\n\u003cp\u003eLa dimetilamilamina tiene una historia farmacológica documentada que precede en décadas a su uso en suplementación deportiva.\u003c\/p\u003e\n\u003c\/header\u003e\n\u003col class=\"fnx-timeline\"\u003e\n\u003cli\u003e\n\u003cspan class=\"fnx-node\"\u003e\u003c\/span\u003e\n\u003cp class=\"fnx-date\"\u003e1940s\u003c\/p\u003e\n\u003ch3\u003eSíntesis por Eli Lilly\u003c\/h3\u003e\n\u003cp\u003eLa DMAA fue sintetizada originalmente como descongestionante nasal. Su actividad simpaticomética quedó documentada en la literatura farmacológica de posguerra bajo distintos isómeros.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan class=\"fnx-node\"\u003e\u003c\/span\u003e\n\u003cp class=\"fnx-date\"\u003e2000s\u003c\/p\u003e\n\u003ch3\u003eEra de pre-entrenamientos\u003c\/h3\u003e\n\u003cp\u003eEl isómero 1,3-DMAA resurge como ingrediente en suplementos deportivos. El isómero 1,4 emerge paralelamente con un perfil de selectividad adrenérgica diferenciado.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan class=\"fnx-node\"\u003e\u003c\/span\u003e\n\u003cp class=\"fnx-date\"\u003e2012 – 2015\u003c\/p\u003e\n\u003ch3\u003eRestricción regulatoria global\u003c\/h3\u003e\n\u003cp\u003eLa FDA y múltiples agencias internacionales emiten alertas y retiran la DMAA de suplementos dietéticos tras reportes de eventos adversos cardiovasculares. La sustancia migra al ámbito RUO.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cspan class=\"fnx-node\"\u003e\u003c\/span\u003e\n\u003cp class=\"fnx-date\"\u003eActualidad\u003c\/p\u003e\n\u003ch3\u003eMaterial de referencia Science.bio\u003c\/h3\u003e\n\u003cp\u003eScience.bio formula 1,4-DMAA HCl como solución líquida de alta pureza para investigación adrenérgica, farmacológica y comparativa de isómeros. CAS 105-41-9 · PubChem CID 7975.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/section\u003e\n\u003csection class=\"fnx-science\"\u003e\n\u003cdiv class=\"fnx-molecule\"\u003e\n\u003cdiv class=\"fnx-orbit fnx-orbit-a\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv class=\"fnx-orbit fnx-orbit-b\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv class=\"fnx-molecule-stage\"\u003e\n\u003csvg class=\"fnx-molecule-svg\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"620\" height=\"340\" role=\"img\"\u003e\n\u003cdefs\u003e\n\u003cfilter id=\"fnxMolGlowR\" x=\"-50%\" y=\"-50%\" width=\"200%\" height=\"200%\"\u003e\n\u003cfegaussianblur stddeviation=\"4\" result=\"b\"\u003e\u003c\/fegaussianblur\u003e\n\u003cfemerge\u003e\u003cfemergenode in=\"b\"\u003e\u003c\/femergenode\u003e\u003cfemergenode in=\"b\"\u003e\u003c\/femergenode\u003e\u003cfemergenode in=\"SourceGraphic\"\u003e\u003c\/femergenode\u003e\u003c\/femerge\u003e\n\u003c\/filter\u003e\n\u003c\/defs\u003e\n\u003cg fill=\"none\" stroke=\"#FF9A8A\" stroke-width=\"3.6\" stroke-linecap=\"round\" stroke-linejoin=\"round\" filter=\"url(#fnxMolGlowR)\"\u003e\n\u003cline x1=\"60\" y1=\"170\" x2=\"130\" y2=\"170\"\u003e\u003c\/line\u003e\n\u003cline x1=\"130\" y1=\"170\" x2=\"165\" y2=\"110\"\u003e\u003c\/line\u003e\n\u003cline x1=\"165\" y1=\"110\" x2=\"235\" y2=\"110\"\u003e\u003c\/line\u003e\n\u003cline x1=\"235\" y1=\"110\" x2=\"270\" y2=\"170\"\u003e\u003c\/line\u003e\n\u003cline x1=\"270\" y1=\"170\" x2=\"340\" y2=\"170\"\u003e\u003c\/line\u003e\n\u003cline x1=\"340\" y1=\"170\" x2=\"375\" y2=\"110\"\u003e\u003c\/line\u003e\n\u003cline x1=\"375\" y1=\"110\" x2=\"445\" y2=\"110\"\u003e\u003c\/line\u003e\n\u003cline x1=\"270\" y1=\"170\" x2=\"270\" y2=\"240\"\u003e\u003c\/line\u003e\n\u003cline x1=\"270\" y1=\"240\" x2=\"340\" y2=\"240\"\u003e\u003c\/line\u003e\n\u003cline x1=\"445\" y1=\"110\" x2=\"510\" y2=\"75\"\u003e\u003c\/line\u003e\n\u003cline x1=\"445\" y1=\"110\" x2=\"510\" y2=\"145\"\u003e\u003c\/line\u003e\n\u003cline x1=\"60\" y1=\"170\" x2=\"60\" y2=\"240\" stroke-dasharray=\"6,4\" opacity=\".5\"\u003e\u003c\/line\u003e\n\u003c\/g\u003e\n\u003ccircle cx=\"445\" cy=\"110\" r=\"20\" fill=\"#3a0a06\"\u003e\u003c\/circle\u003e\n\u003ctext x=\"445\" y=\"118\" text-anchor=\"middle\" font-size=\"21\" font-weight=\"800\" fill=\"#FFD0C8\" font-family=\"Inter,sans-serif\"\u003eN\u003c\/text\u003e\n\u003ccircle cx=\"60\" cy=\"170\" r=\"16\" fill=\"#3a0a06\"\u003e\u003c\/circle\u003e\n\u003ctext x=\"60\" y=\"177\" text-anchor=\"middle\" font-size=\"17\" font-weight=\"800\" fill=\"#FFD0C8\" font-family=\"Inter,sans-serif\"\u003eC\u003c\/text\u003e\n\u003ccircle cx=\"60\" cy=\"252\" r=\"16\" fill=\"#2a0605\"\u003e\u003c\/circle\u003e\n\u003ctext x=\"60\" y=\"259\" text-anchor=\"middle\" font-size=\"14\" font-weight=\"700\" fill=\"#f87171\" font-family=\"Inter,sans-serif\"\u003eCl-\u003c\/text\u003e\n\u003ctext x=\"516\" y=\"72\" text-anchor=\"middle\" font-size=\"14\" font-weight=\"700\" fill=\"#fca5a5\" font-family=\"Inter,sans-serif\"\u003eCH3\u003c\/text\u003e\n\u003ctext x=\"516\" y=\"158\" text-anchor=\"middle\" font-size=\"14\" font-weight=\"700\" fill=\"#fca5a5\" font-family=\"Inter,sans-serif\"\u003eH\u003c\/text\u003e\n\u003ctext x=\"355\" y=\"262\" text-anchor=\"middle\" font-size=\"14\" font-weight=\"700\" fill=\"#fca5a5\" font-family=\"Inter,sans-serif\"\u003eCH3\u003c\/text\u003e\n\u003c\/svg\u003e\n\u003cdiv class=\"fnx-platform\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-molecule-meta\"\u003e\n\u003cstrong\u003e1,4-DMAA · HCl\u003c\/strong\u003e \u003cspan\u003eC7H17N · HCl · 151.68 g\/mol\u003cbr\u003eCAS 105-41-9 · PubChem CID 7975\u003c\/span\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-science-copy\"\u003e\n\u003cp class=\"kicker\"\u003eLA MOLÉCULA\u003c\/p\u003e\n\u003ch2\u003eAmina alifática ramificada.\u003c\/h2\u003e\n\u003cp class=\"fnx-science-lead\"\u003eEl 1,4-DMAA es una amina primaria de cadena corta con ramificación en posición 4. Su estructura sencilla concentra alta actividad adrenérgica con perfil de selectividad distinto al isómero 1,3.\u003c\/p\u003e\n\u003cdiv class=\"fnx-topics\"\u003e\n\u003carticle class=\"fnx-topic\"\u003e\u003cspan\u003e01\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eCadena C7 ramificada\u003c\/h3\u003e\n\u003cp\u003eSiete carbonos con ramificación en posición 4 — la misma longitud de cadena que el isómero 1,3 pero con punto de ramificación desplazado.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-topic\"\u003e\u003cspan\u003e02\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eGrupo amino primario\u003c\/h3\u003e\n\u003cp\u003eEl nitrógeno terminal con dos metilos confiere la actividad simpaticomética. La posición relativa de la amina determina la selectividad adrenérgica.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-topic\"\u003e\u003cspan\u003e03\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eSal clorhidrato\u003c\/h3\u003e\n\u003cp\u003eLa formulación como HCl garantiza estabilidad en solución acuosa, solubilidad reproducible y facilidad de dosificación en protocolos de investigación.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-topic\"\u003e\u003cspan\u003e04\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eSelectividad a2 \/ TAAR1\u003c\/h3\u003e\n\u003cp\u003eLas variaciones de potencia del isómero 1,4 sobre receptores a2 y TAAR1 son el foco principal de investigación comparativa entre isómeros DMAA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"fnx-benefits\"\u003e\n\u003cdiv class=\"fnx-benefits-intro\"\u003e\n\u003cp class=\"kicker\"\u003eMECANISMO DE ACCIÓN\u003c\/p\u003e\n\u003ch2\u003eCómo actúa el 1,4-DMAA.\u003c\/h2\u003e\n\u003cp\u003eSeis vías documentadas en la literatura farmacológica. Sin afirmaciones clínicas — solo fisiología adrenérgica.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-benefits-grid\"\u003e\n\u003carticle class=\"fnx-benefit\"\u003e\u003cspan class=\"fnx-benefit-num\"\u003e01\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eLiberación de catecolaminas\u003c\/h3\u003e\n\u003cp\u003ePromueve liberación de norepinefrina y dopamina en terminales sinápticas e inhibe su recaptación, amplificando la señal adrenérgica.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-benefit\"\u003e\u003cspan class=\"fnx-benefit-num\"\u003e02\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eAgonismo a\/b-Adrenérgico\u003c\/h3\u003e\n\u003cp\u003eActiva receptores centrales y periféricos incrementando FC, presión arterial y termogénesis de forma rápida y dosis-dependiente.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-benefit\"\u003e\u003cspan class=\"fnx-benefit-num\"\u003e03\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eEstimulación SNC\u003c\/h3\u003e\n\u003cp\u003eIncrementa alerta, vigilia y enfoque mental. Reduce percepción de fatiga central durante esfuerzo físico de alta intensidad.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-benefit\"\u003e\u003cspan class=\"fnx-benefit-num\"\u003e04\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eEfecto termogénico\u003c\/h3\u003e\n\u003cp\u003eAumenta tasa metabólica basal y potencia oxidación de ácidos grasos libres como sustrato energético principal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-benefit\"\u003e\u003cspan class=\"fnx-benefit-num\"\u003e05\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eSelectividad a2 \/ TAAR1\u003c\/h3\u003e\n\u003cp\u003eEl isómero 1,4 presenta variaciones de potencia sobre receptores a2 y TAAR1 respecto al 1,3-DMAA, relevantes para investigación comparativa.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-benefit\"\u003e\u003cspan class=\"fnx-benefit-num\"\u003e06\u003c\/span\u003e\n\u003cdiv\u003e\n\u003ch3\u003eMaterial de referencia certificado\u003c\/h3\u003e\n\u003cp\u003eAlta pureza y concentración declarada (100 mg\/mL) para garantizar reproducibilidad en protocolos de investigación comparativa.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/article\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"fnx-audience\"\u003e\u003cheader\u003e\n\u003cp class=\"kicker\"\u003eIDENTIDAD QUÍMICA\u003c\/p\u003e\n\u003ch2\u003ePerfil molecular.\u003c\/h2\u003e\n\u003c\/header\u003e\n\u003cdiv class=\"fnx-audience-grid\"\u003e\n\u003carticle class=\"fnx-audience-item\"\u003e\n\u003ch3\u003eFórmula · C7H17N · HCl\u003c\/h3\u003e\n\u003cp\u003eAmina alifática primaria de cadena ramificada (7 carbonos), formulada como sal clorhidrato para estabilidad y solubilidad en matrices acuosas.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-audience-item\"\u003e\n\u003ch3\u003eCAS 105-41-9 · PubChem CID 7975\u003c\/h3\u003e\n\u003cp\u003eMasa molecular 151.68 g\/mol. Identificadores verificables en PubChem y bases de datos de referencia farmacológica internacional.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-audience-item\"\u003e\n\u003ch3\u003ePresentación · 100 mg\/mL · 30 mL\u003c\/h3\u003e\n\u003cp\u003e3,000 mg totales en solución. Gotero de precisión para dosificación exacta de 10–25 mg por evento (0.1–0.25 mL). Almacenar a 15–25 °C, protegido de luz directa.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-audience-item\"\u003e\n\u003ch3\u003eClasificación RUO\u003c\/h3\u003e\n\u003cp\u003eNo aprobado para uso en humanos ni animales. Exclusivamente para investigación científica en laboratorio por personal calificado.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"fnx-questions\"\u003e\u003cheader\u003e\n\u003cp class=\"kicker\"\u003ePREGUNTAS CLAVE\u003c\/p\u003e\n\u003ch2\u003eResuelve tus dudas.\u003c\/h2\u003e\n\u003c\/header\u003e\n\u003cdiv\u003e\n\u003carticle class=\"fnx-question\"\u003e\n\u003ch3\u003e¿Qué diferencia al isómero 1,4 del 1,3-DMAA?\u003c\/h3\u003e\n\u003cp\u003eEl isómero 1,4 presenta mayor selectividad adrenérgica y variaciones en potencia sobre receptores a2 y TAAR1. Su perfil farmacológico diferenciado lo hace relevante para investigación comparativa entre isómeros.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-question\"\u003e\n\u003ch3\u003e¿Por qué está disponible solo como RUO?\u003c\/h3\u003e\n\u003cp\u003eLa FDA y múltiples agencias internacionales restringieron la DMAA en suplementos dietéticos tras reportes de eventos adversos cardiovasculares. Science.bio lo formula como material de referencia certificado exclusivamente para investigación científica.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-question\"\u003e\n\u003ch3\u003e¿Cuál es el rango de dosis en protocolos de investigación?\u003c\/h3\u003e\n\u003cp\u003eLa literatura científica documenta rangos de 10–25 mg por dosis (0.1–0.25 mL de la solución 100 mg\/mL), con intervalos mínimos de 48–72 horas entre administraciones para minimizar tolerancia.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003carticle class=\"fnx-question\"\u003e\n\u003ch3\u003e¿Cómo se almacena y manipula correctamente?\u003c\/h3\u003e\n\u003cp\u003eTemperatura ambiente (15–25 °C), protegido de luz directa y humedad. El frasco gotero permite dispensación controlada. No refrigerar. Verificar integridad del sello antes de cada uso.\u003c\/p\u003e\n\u003c\/article\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\u003csection class=\"fnx-close\"\u003e\n\u003cdiv class=\"fnx-close-copy\"\u003e\n\u003cp class=\"kicker\"\u003eRESEARCH USE ONLY · SCIENCE.BIO\u003c\/p\u003e\n\u003ch2\u003e1,4-DMAA HCl · 100 mg\/mL · 30 mL · 3,000 mg totales.\u003c\/h2\u003e\n\u003cp\u003eAmina simpaticomética de alta pureza en solución líquida. Material de referencia certificado para investigación adrenérgica. CAS 105-41-9 · Solo para investigación científica.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fnx-actions\"\u003e\n\u003ca class=\"fnx-btn fnx-btn-primary\" href=\"#AddToCart\"\u003eAgregar al carrito\u003c\/a\u003e \u003ca class=\"fnx-btn fnx-btn-secondary\" href=\"https:\/\/api.whatsapp.com\/send\/?phone=525542463084\u0026amp;text=Hola%2C%20tengo%20una%20duda%20sobre%201%2C4-DMAA%20HCl%20Science.bio\u0026amp;type=phone_number\u0026amp;app_absent=0\" rel=\"noopener noreferrer\" target=\"_blank\"\u003eConsultar por WhatsApp\u003c\/a\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv style=\"margin-top: 24px; padding: 14px 32px; background: rgba(16,3,2,.95); border: 1px solid rgba(248,113,113,.1); border-radius: 14px;\"\u003e\n\u003cp style=\"margin: 0; color: #6b3030; font-size: 11.5px; line-height: 1.7; text-align: center;\"\u003eEsta sustancia es para investigación y no para consumo humano o veterinario. · CAS 105-41-9 · Science.bio · Nootrópicos México.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Science.bio","offers":[{"title":"Default Title","offer_id":43754934927427,"sku":"SCIENCEBIO-14DMAA-3000MG-LIQ","price":1399.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1156\/1718\/files\/image_115e1bc0-d96b-4e73-b518-70d33a272f0d.png?v=1776885257","url":"https:\/\/nootropicosmexico.com\/products\/1-4-dmaa-hcl-3000-mg-100-mg-ml-30-ml-science-bio-copia","provider":"Nootrópicos México ","version":"1.0","type":"link"}